Table 1 Incidence and % Incidence of Neoplastic Lesions by Tissue for Terminal Kill and Interim Death Animals Combined

	MALES								FEMALES							
	0ppm		500ppm		1500ppm		5000ppm		0ppm		500ppm		1500ppm		5000ppm	
Number of Mice	51		51		51		51		51		51		51		51	
CONDITION	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**
ADRENAL GLAND*																
Cortical adenoma b	3	6	0	0	0	0	3	6	0	0	0	0	0	0	0	0
Cortical carcinoma m	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BONE																
Osteoma b	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0	0
BONE MARROW																
Lipoma b	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Histiocytic sarcoma m	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2
BRAIN *																
Meningeal sarcoma m	0	0	0	0	0	0	1	2	0	0	0	0	0	0	0	0
Oligodendroglioma m	1	2	0	0	0	0	0	0	1	2	0	0	0	0	0	0
HARDERIAN GLAND**																
Adenoma b	4	8	0	0	0	0	2	4	1	2	0	0	0	0	2	4
Adenocarcinoma m	0	0	0	0	0	0	0	0	2	4	0	0	0	0	0	0
INTESTINAL TUMOUR																
Adenoma b	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0	0
KIDNEY																
Haemangiosarcoma m	0	0	0	0	1	2	0	0	0	0	0	0	0	0	0	0
LIVER*																
Hepatocellular adenoma b	1	2	1	2	4	8	2	4	0	0	0	0	0	0	0	0
Hepatocellular carcinoma m	6	12	11	22	7	14	4	8	0	0	1	2	0	0	0	0
Combined	7	14	12	24	11	22	6	12	0	0	1	2	0	0	0	0
Haemangioma b	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0
Haemangiosarcoma m	2	4	1	2	1	2	1	2	0	0	0	0	1	2	0	0
LUNG*																
Adenoma b	9	18	7	14	9	18	4	8	2	4	4	8	2	4	2	4
Adenocarcinoma m	5	10	5	10	7	14	11	22	5	10	2	4	2	4	3	6
Combined	14	28	12	24	16	32	15	30	7	14	6	12	4	8	5	10
MAMMARY GLAND																
Adenocarcinoma m	0	0	0	0	0	0	0	0	0	0	1	2	3	6	1	2
Adenosquamous carcinoma m	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0

* Group 1 male % based on 50 animals ** Group 1 male % based on 49 animals

Table 1 Incidence and % Incidence of Neoplastic Lesions by Tissue for Terminal Kill and Interim Death Animals Combined (continued)

	MALES								FEMALES							
	0ppm		500ppm		1500ppm		5000ppm		0ppm		500ppm		1500ppm		5000ppm	
Number of Mice	51		51		51		51		51		51		51		51	
CONDITION	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**
MESENTERIC LYMPH NODE																
Histiocytic sarcoma m	0	0	0	0	0	0	0	0	2	4	0	0	0	0	1	2
OVARY																
Luteoma b									1	2	1	2	1	2	1	2
Haemangioma b									0	0	0	0	0	0	1	2
Sertoli cell tumour b									0	0	0	0	0	0	1	2
Cystadenoma b									0	0	0	0	0	0	2	4
Anaplastic sarcoma m									0	0	1	2	0	0	0	0
PANCREAS																
Islet cell adenocarcinoma m	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0	0
PITUITARY																
Adenoma b	0	0	0	0	0	0	0	0	0	0	1	2	0	0	2	4
SEMINAL VESICLE																
Adenoma b	2	4	0	0	0	0	0	0								
Leiomyosarcoma m	0	0	0	0	0	0	1	2								
SKIN/SUBCUTIS																
Fibrosarcoma m	0	0	3	6	2	4	1	2	0	0	0	0	0	0	0	0
Haemangiosarcoma m	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0
SPLEEN																
Haemangioma b	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Haemangiosarcoma m	0	0	0	0	0	0	0	0	1	2	0	0	0	0	1	2
TESTIS																
Interstitial cell tumour b	2	4	0	0	0	0	0	0								
THYMUS																
Histiocytic sarcoma m	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0
UTERUS																
Endometrial stromal polyp b									2	4	2	4	3	6	4	8
Haemangioma b									0	0	1	2	0	0	0	0
Leiomyoma b									0	0	0	0	1	2	0	0
Squamous cell carcinoma m									1	2	0	0	0	0	0	0
Histiocytic sarcoma m									2	4	2	4	0	0	1	2
Leiomyosarcoma m									1	2	0	0	0	0	0	0

Table 1 Incidence and % Incidence of Neoplastic Lesions by Tissue for Terminal Kill and Interim Death Animals Combined (continued)

	MALES								FEMALES							
	0ppm		500ppm		1500ppm		5000ppm		0ppm		500ppm		1500ppm		5000ppm	
Number of Mice	51		51		51		51		51		51		51		51	
CONDITION	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**
ABDOMINAL																
Lipoma b	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0	0
Mesothelioma m	0	0	0	0	0	0	1	2	0	0	0	0	0	0	0	0
Anaplastic sarcoma m	0	0	0	0	0	0	1	2	0	0	0	0	0	0	0	0
LYMPHOID/HAEMOPOIETIC ***																
Myeloid leukaemia m	0	0	1	2	0	0	0	0	0	0	0	0	1	2	0	0
Malignant lymphoma m	0	0	1	2	2	4	5	10	11	22	8	16	10	20	11	22
****Histiocytic sarcoma m	0	0	0	0	0	0	0	0	4	8	2	4	1	2	3	6
Combined	0	0	2	4	2	4	5	10	15	29	10	20	12	24	14	28
OVERALL TUMOUR INCIDENCE																
Primary benign tumours	15	29	6	12	9	18	7	14	5	10	6	12	6	12	9	18
Primary malignant tumours	14	28	20	39	17	33	20	39	23	45	15	29	17	33	18	35
Multiple benign tumours	6	12	2	4	4	8	1	2	4	8	4	8	1	2	7	14
Multiple malignant tumours	1	2	2	4	3	6	5	10	4	8	2	4	1	2	1	2

*** Histiocytic sarcomas are not generally regarded as lymphoid in origin but are usefully included here

**** Based on incidence from all sites and not additional to those reported for individual sites